A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer
Clinical trial NCT06745193 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06745193
- Sponsor
- Peking University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-01
- Primary completion
- 2027-02-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.